panCELLa

The advent of human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells had a paradigm-shifting effect on regenerative medicine -- a powerful new treatment against diseases underlined by cell loss, tissue degeneration and aging. With these applications came critical and important challenges posing safety risks to patients: uncontrolled proliferation and genetic mutations. panCELLa has developed a solution to these challenges.
Incorporated in August 2015, panCELLa was founded by Dr. Andras Nagy and Dr. Armand Keating based on Dr. Nagy’s ground-breaking work in the area of stem cell research. Through panCELLa, Dr. Keating and Dr. Nagy are seeking to create an effective cell therapy derived from stem cells, which are modified to provide a very high level of safety before and after the cells are introduced to the patient.
panCELLa’s “FailSafe” solution provides precisely engineered cells with quantifiable and complete control over a cell therapy. Dr. Nagy, panCELLa’s founder, often notes that just as man is the only creature to light a fire, panCELLa “dares” to use stem cells as a therapeutic tool in the treatment of degenerative and malignant diseases because we alone offer a “FailSafe Cell System”. panCELLa’s exclusive “FailSafe” cells have mitigated the risk of cells going awry allowing:
> Regulators to determine the risk of a given cell therapy;
> Doctors and Clinicians to quantify the level of risk; and,
> Patients to make an informed decision.
panCELLa’s “FailSafe” technology precisely controls undesirable and deregulated cell division and mutations by linking a drug inducible “suicide gene” tightly to cell proliferation. This mechanism enables dividing, potentially malignant cells to be efficiently and reliably controlled or eliminated at any time during the treatment of a patient. The “FailSafe Cell System” does not impede the therapeutic properties of cell treatments: pluripotent stem cells are still capable of differentiation in a multitude of potential therapeutic cell types.